Synairgen plc (SYGGF)

0.0505 0.0000 (0.00%) As of 03:49PM EDT. Market open.

Synairgen plc

Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton SO16 6YD
United Kingdom
44 23 8051 2800
https://www.synairgen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 34

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard Marsden	CEO, MD & Executive Director	407.7k	N/A	1967
Prof. Stephen T. Holgate CBE, M.D.	Co-Founder, Non-Executive Director & Member of Scientific Advisory Board	54.69k	N/A	1947
Dr. Phillip David Monk	Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director	298.32k	N/A	1969
Prof. Donna Davies	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Prof. Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Joseph Tregonning Colliver F.C.A.	CFO & Executive Director	N/A	N/A	1980
Dr. Gareth E. Walters Ph.D.	Chief Regulatory Officer	N/A	N/A	1959
Ms. Jody Brookes	Senior VP & Head of Clinical Operations	N/A	N/A	N/A
Mr. Richard Francis	Senior VP and Head of CMC & Quality	N/A	N/A	N/A
Dr. Victoria Tear	Head of Laboratory	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Corporate governance

Synairgen plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.